Carisbamate is being developed for adjuvant treatment of partial onset epilepsy. Carisbamate produces anticonvulsant effects in primary generalized, complex partial and absence-type seizure models, and exhibits neuroprotective and antiepileptogenic properties in rodent epilepsy models. Neuroprotective & Neuroresearch Product. Acts as a novel neuromodulator with a little evidence of CYP metabolism.
